Supplementary Online Content

Brown HE, Freudenreich O, Fan X, et al. Efficacy and tolerability of adjunctive intravenous sodium nitroprusside treatment for outpatients with schizophrenia: a randomized clinical trial. *JAMA Psychiatry*. Published online March 27, 2019. doi:10.1001/jamapsychiatry.2019.0151

eFigure 1. Sequential Parallel Comparison Design (SPCD)


eFigure 2. Study Schema

eTable 1. Positive and Negative Syndrome Scale (PANSS) Scores Stratified by Treatment Status

eTable 2. Positive and Negative Syndrome Scale (PANSS) Scores Stratified by PANSS-Negative Subscores

eTable 3. Percentage of Participants Reporting Experiencing SAFTEE Symptoms at "Moderate" or "Severe" Level for the 10 Most Frequently Reported Symptoms Post Randomization


This supplementary material has been provided by the authors to give readers additional information about their work.



eFigure 1. Sequential Parallel Comparison Design (SPCD)

SPCD=Sequential Parallel Comparison Design; SNP=sodium nitroprusside





SNP=sodium nitroprusside; MGH=Massachusetts General Hospital

eTable 1. Positive and Negative Syndrome Scale (PANSS) Scores Stratified by Treatment Status

		Cloz	apine	No Clozapine			
		n	=19	n=33			
		p-value	estimate	p-value	estimate		
Primary Outcome Measure							
	PANSS total (SPCD analysis)	0.41	-1.85	0.57	-1.50		
Secondary Outcome Measure							
	PANSS - positive (SPCD analysis)	0.41	-0.83	0.55	-0.60		
	PANSS - negative (SPCD analysis)	0.79	0.29	0.79	-0.22		
	PANSS - general (SPCD analysis)	0.55	-1.08	0.97	0.06		

SPCD=Sequential Parallel Comparison Design; PANSS=Positive and Negative Syndrome Scale

eTable 2. Positive and Negative Syndrome Scale (PANSS) Scores Stratified by
PANSS-Negative Subscores

		High PANS n=27		Low PANSS-N n=25		
		p-value	estimate		p-value	estimate
Prin	nary Outcome Measure					
	PANSS total (SPCD analysis)	0.23	-2.95		0.66	1.17
Secondary Outcome Measure						
	PANSS - positive (SPCD analysis)	0.24	-1.06		0.86	0.15
	PANSS - negative (SPCD analysis)	0.71	-0.35		0.94	-0.08
	PANSS - general (SPCD analysis)	0.25	-1.59		0.41	1.30

SPCD=Sequential Parallel Comparison Design; PANSS=Positive and Negative Syndrome Scale; PANSS-N= Positive and Negative Syndrome Scale, negative symptoms subscore

	SNP SNP			Placebo SNP n=16			Placebo Placebo n=18		Total
SAFTEE Symptoms	n=	n=18							n=52
	BL	FU		BL	FU		BL	FU	FU
Hearing or seeing things	22%	33%		25.0%	31%		22%	17%	27%
Feeling drowsy or sleepy	17%	22.2%		0.0%	25%		22%	22%	23%
Trouble concentrating	17%	11.1%		6%	19%		22%	28%	19%
Poor memory	11%	5.6%		6%	25%		28%	22%	17%
Trouble Sleeping	17%	11.1%		6%	13%		28%	22%	15%
Feeling nervous or hyper	6%	5.6%		19%	19%		33%	22%	15%
Dry mouth	6%	5.6%		13%	25%		11%	17%	15%
Frequent need to urinate	0%	5.6%		6%	19%		11%	17%	14%
Stuffy nose	6%	5.6%		6%	19%		17%	11%	12%
Hot flashes	0%	11.1%		6%	6%		6%	17%	12%

eTable 3. Percentage of Participants Reporting Experiencing SAFTEE Symptoms at "Moderate" or "Severe" Level for the 10 Most Frequently Reported Symptoms Post Randomization

BL = reported at baseline; FU = reported at any assessment thereafter ("follow-up"), including 7 hours after infusions 1 and 2, Baseline 2 (Day 14), and final follow-up, including early termination visits; SNP = sodium nitroprusside; SAFTEE = Systematic Assessment for Treatment Emergent Effects